123 related articles for article (PubMed ID: 1374180)
1. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer?
Arai Y; Takeuchi H; Oishi K; Yoshida O
Prostate; 1992; 20(3):169-77. PubMed ID: 1374180
[TBL] [Abstract][Full Text] [Related]
2. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
[TBL] [Abstract][Full Text] [Related]
3. Correlation between bone scans and serum levels of osteocalcin, prostate-specific antigen, and prostatic acid phosphatase in monitoring patients with disseminated cancer of the prostate.
Tarle M; Kovaćić K; Strelkov-Alfirević A
Prostate; 1989; 15(3):211-9. PubMed ID: 2479938
[TBL] [Abstract][Full Text] [Related]
4. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
5. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
[TBL] [Abstract][Full Text] [Related]
6. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation on serum osteocalcin in advanced prostate cancer patients].
Abe H; Nakagami YJ; Ito H; Ikeda K; Oka F; Niwa N
Hinyokika Kiyo; 1991 Aug; 37(8):877-80. PubMed ID: 1720275
[TBL] [Abstract][Full Text] [Related]
8. [The possibility of the serum concentration of osteocalcin determination in lung cancer patients with suspected bone metastases].
Weissensteiner J; Babušíková E
Klin Onkol; 2015; 28(1):51-6. PubMed ID: 25692755
[TBL] [Abstract][Full Text] [Related]
9. [Carcinoma of the prostate: correlation between local staging and systemic progression].
Rosi P; Marzi M; Mearini E; Bracarda S; Valli PP; Petroni PA; Porena M
Arch Ital Urol Androl; 1996 Dec; 68(5 Suppl):91-5. PubMed ID: 9162385
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer.
Imamoto T; Suzuki H; Akakura K; Komiya A; Nakamachi H; Ichikawa T; Igarashi T; Ito H
Endocr J; 2001 Oct; 48(5):573-8. PubMed ID: 11789562
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.
Koeneman KS; Kao C; Ko SC; Yang L; Wada Y; Kallmes DF; Gillenwater JY; Zhau HE; Chung LW; Gardner TA
World J Urol; 2000 Apr; 18(2):102-10. PubMed ID: 10854144
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
14. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer.
Arai Y; Yoshiki T; Yoshida O
J Urol; 1990 Dec; 144(6):1415-9. PubMed ID: 1700155
[TBL] [Abstract][Full Text] [Related]
16. Osteocalcin is not a marker of progress in multiple myeloma. Le Groupe d'Etude et de Recherche sur le Myélome (GERM).
Mejjad O; Le Loët X; Basuyau JP; Ménard JF; Jego P; Grisot C; Daragon A; Grosbois B; Euller-Ziegler L; Monconduit M
Eur J Haematol; 1996; 56(1-2):30-4. PubMed ID: 8599990
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of serum osteocalcin in patients with bone metastasis of breast cancer].
Suzuki S; Nomizu T; Nihei M; Rokkaku Y; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1989 Oct; 24(10):2386-93. PubMed ID: 2614177
[TBL] [Abstract][Full Text] [Related]
18. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
19. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Loeb S; Makarov DV; Schaeffer EM; Humphreys EB; Walsh PC
J Urol; 2010 Jul; 184(1):157-61. PubMed ID: 20483148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
